The Chemours (US.CC)
Capital Allocation Audit · Period: 2011 – 2026
Key Metrics
US.CC · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 211.4% | ↑ |
| ROE | -13.5% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 20.42 | ↓ |
| Gross Margin | 15.4% | ↓ |
US.CC (The Chemours) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 211.4% ↑ ROE -13.5% ↓ Cash Conversion - → D/E Ratio 20.42 ↓ Gross Margin 15.4% ↓
Key Metrics
US.CC (The Chemours) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 211.4% ↑ROE -13.5% ↓Cash Conversion - →D/E Ratio 20.42 ↓Gross Margin 15.4% ↓Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies